Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)

BACKGROUND: This study aimed to investigate whether schedule modification is safe and effective in patients intolerant to the standard eribulin dose and schedule. METHODS: Patients with metastatic breast cancer (MBC) treated with both anthracycline and taxane and ≤ 3 prior regimens of chemotherapy f...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohtani, Shoichiro, Nakayama, Takahiro, Yoshinami, Tetsuhiro, Watanabe, Ken-ichi, Hara, Fumikata, Sagara, Yasuaki, Kawaguchi, Hidetoshi, Higaki, Kenji, Matsunami, Nobuki, Hasegawa, Yoshie, Takahashi, Masato, Mizutani, Makiko, Morimoto, Takashi, Sato, Masako, Itoh, Mitsuya, Morita, Satoshi, Masuda, Norikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996009/
https://www.ncbi.nlm.nih.gov/pubmed/29435730
http://dx.doi.org/10.1007/s12282-018-0843-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996009/
https://www.ncbi.nlm.nih.gov/pubmed/29435730
http://dx.doi.org/10.1007/s12282-018-0843-y

Ejemplares similares